Fabian Johnston, MD, MHS
Dr. Johnson is a highly esteemed surgical oncologist who holds the titles of Associate Professor in the Department of Surgery, and Division Chief of the Division of Gastrointestinal Oncology, and Director of the Complex General Surgical Oncology Program at Johns Hopkins Medicine. He specializes in caring for patients with colorectal, gastroesophageal, and gastrointestinal tumors, including malignant peritoneal mesothelioma, and is an expert in the use of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for its treatment.[1]
Education and Career
Dr. Johnston earned his undergraduate degree at the State University of New York at Stony Brook and his medical degree from the Pennsylvania State University College of Medicine. He completed residencies at the Louisiana State University School of Medicine and Washington University in St. Louis, then completed a fellowship in Complex General Surgical Oncology at Johns Hopkins University. He also earned a Masters in Health Science at Hopkins’ Bloomberg School of Public Health.[1]
Professional Memberships and Activities
Dr. Johnston is actively involved in many professional medical organizations, including:[1]
- American College of Surgeons, 2005
- National Medical Association, 2010
- Society of Surgical Oncology, 2011
- Society of Black Academic Surgeons, 2010
- Americas Hepato-Pancreato-Biliary Association, 2010
- American Society of Clinical Oncology, 2012
- Association of Academic Surgeons, 2014
- Society for Surgery of the Alimentary Tract, 2015
Research
Dr. Johnston’s research interests focus on innovative patient-centered models to improve the use of palliative care for patients with advanced gastrointestinal malignancies. He is also interested in improving the quality of life for the most severely ill and vulnerable patient populations. His research is funded through a K08 career award from the Agency for Health Care Research and Quality. He is a coinvestigator on multiple PCORI awards and has authored and co-authored numerous publications about clinical trials and studies in which he has participated.[1] The most recent of these include:[2]
Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative. Feb 2024. Nadege Fackche. Ryan K. Schmocker. Richard Nudotor[…] Jonathan Greer. Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, C…
ASO Author Reflections: To Test or Not to Test: How Do We Decide the Optimal Site for Organoid Generation in Patients with Metastatic Disease? Jan 2024. Shannon N. Radomski, Jonathan Greer, Fabian Johnston, Andrew J. Ewald
ASO Visual Abstract: Intra- and Interpatient Drug Response Heterogeneity Exist in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Non-gynecologic Cancers, Jan 2024. Shannon N. Radomski, Matthew Dunworth, Junior J. West[…], Andrew J. Ewald
Intra- and Interpatient Drug Response Heterogeneity Exist in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Nongynecologic Cancers, Jan 2024. Shannon N Radomski, Matthew Dunworth, Junior J West[…] Andrew J Ewald. Select patients with peritoneal metastases are treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). We assayed for intra- and interpatient drug response heterogeneity through testing of patient-derived tumor organoids (PDTOs). PDTOs were generated from CRS/HIPEC patients from December 2021 to September 2022…
Caregiver‐reported quality of communication in pancreatic and periampullary cancer. Dec 2023. Zhi Ven Fong, Jonathan Teinor, Lilly Engineer[…] Jennifer L. Wolff. Background Communication between caregivers and clinical team members is critical for transitional care, but its quality and potential impact on outcomes are not well understood. This study reports on the caregiver‐reported quality of communication with clinical team members in the post pancreatectomy period and examines associations of these reports wi…
ASO Visual Abstract: Predictors of Financial Toxicity Risk Among Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC). Dec 2023. Yusuf Ciftci, Shannon N. Radomski, Fabian Johnston, Jonathan Greer
